Press Releases

Press Releases

Date Title and Summary Additional Formats
Nov 26, 2019 Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
CORAL GABLES, Fla. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Nov 12, 2019 Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020 -Company to Host Quarterly Conference
Oct 31, 2019 Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019
CORAL GABLES, Fla. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Oct 30, 2019 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints MuSK-Myasthenia Gravis Phase
Sep 25, 2019 Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
CORAL GABLES, Fla. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Sep 23, 2019 Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources
CORAL GABLES, Fla. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital resources. The Company is reporting that it is not aware of any information about the
Sep 13, 2019 Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
CORAL GABLES, Fla. , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019 . The Company believes that the culmination of an offering at the
Sep 11, 2019 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to
Aug 28, 2019 Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019
CORAL GABLES, Fla. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Aug 07, 2019 Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,

Displaying 1 - 10 of 24